News (1)
Something happened? CCP experts admit that domestic vaccines are not safe enough, call on ordinary people not to get vaccinated temporarily
Reporter : Yang Zheng / Editor : Yuan Mingqing / https://www.soundofhope.org/post/435145 / Translation, editing : Gan Yung Chyan, KUCINTA SETIA
China's SARS-CoV-2 (CCP virus) vaccines are still in the experimental stage and has been put into use on a large scale. The official has also been advocating for domestic vaccines, but recently an expert suddenly said that the effectiveness and protective effect of the vaccine is still unclear, and it is recommended that ordinary people not be vaccinated for the time being, which has aroused greater concerns from the outside world.
On 21 October, Wu Zunyou, chief epidemiologist of the China CDC, attended the Southeast Science and Technology Forum and gave a special report entitled "SARS-CoV-2 Epidemic Situation and Prevention and Control Strategies".
Wu Zunyou pointed out that at present, China's novel coronavirus pneumonia vaccine has not yet completed the Phase III clinical trial. "When the effectiveness and protective effect of the vaccine are not particularly clear, ordinary people do not need to consider vaccination for the time being."
He also said, "Even if the results of the Phase III clinical trial come out, it will be a phased result, and absolute safety cannot be 100% guaranteed."
Mainland Chinese media have always reported good news but not worries about domestic vaccines. Even when Wu Zunyou’s remarks were reported, he did not forget to add the sentence "In the past few days, the good news about the domestic (CCP virus) vaccine continues to be screened." In such a public opinion environment, Suddenly, an internal expert came out to say that the vaccine is not absolutely safe, and it is recommended that ordinary people not vaccinate it temporarily, which makes the outside world worry about whether there is a major problem with the domestic vaccine.
In fact, it has been reported one after another that Chinese "subjects" developed drowsiness, fatigue, dizziness, fever and other symptoms after being vaccinated. However, at the press conference of the Joint Prevention and Control Mechanism of the State Council of the Communist Party of China on October 20, the Ministry of Science and Technology Tian Baoguo, deputy director of the Department of Science and Technology of Social Development, said that adverse reactions to any vaccine may occur after R&D trials or after marketing. The reports received so far are all mild, "preliminarily showing the good safety of (vaccine). ".
In contrast, after discovering that five test volunteers had symptoms such as fatigue, fever, and headaches that lasted for a day after being vaccinated, Modena, a US biotech company, cautiously slowed down.
At the press conference on 20 October, the official also announced that so far about 60,000 people in China have received the test vaccination, and said that it will be further expanded in the future.
China’s approach has aroused concerns from the outside world. Dr. Amesh A. Adalja, a senior scholar at the Johns Hopkins University Center for Health Security, once told VOA that the third phase was not completed. Before large-scale trials, if experimental vaccines are widely introduced, “the risk of safety or efficacy signals may appear, and other vaccines under development may be contaminated.” “Because the third phase of clinical trials can provide important information, this is also necessary the reason for the third phase of testing. If the vaccine is tested on only a few people, it is difficult to know exactly how the vaccine works."
Raina MacIntyre, a scholar at the University of New South Wales in Australia, also said that it is not recommended to use the vaccine urgently before clinical trials. In the past, there have been serious problems due to defective vaccines. For example, in 2017, children who were vaccinated against Sanofi dengue fever became more sick after being infected.
Jin Dongyan, a professor in the Department of Biochemistry at the Li Ka-shing School of Medicine of the University of Hong Kong, also pointed out worrisomely that the vaccine has not yet completed the Phase III trial and can be used if the situation is critical. The review system was overturned.
It is reported that since September this year, more than 740,000 people in Zhejiang Province have been vaccinated with Sinovac Biotech's vaccine. Brazil has 9,000 volunteers tested for the same vaccine, and 35% of the subjects have side effects. The country has declared that it has refused to use it.
__________
News (2)
35% of Brazilian subjects have side effects and abandoned the purchase of Chinese "cabbage price" vaccine
Reporter : Zhong Jingming / Editor: Mei Lan / https://www.ntdtv.com/gb/2020/10/22/a102969254.html / Translation, editing : Gan Yung Chyan, KUCINTA SETIA
Brazil has announced the purchase of 46 million doses of Chinese-made Chinese-made virus vaccine, which was suddenly stopped by the President on Wednesday (21 October). Previously, the Brazilian local government had stated that as many as 35% of the 9,000 people in the country who were tested for the vaccine had side effects. According to previous Hong Kong media reports, these 46 million doses of Chinese vaccines are sold at "cabbage prices."
Brazilian President Bolsonaro made it clear on 21 October that he would not purchase vaccines from China's Sinovac Biotech, so that the Brazilian people would become "white rats" for Chinese experiments. The Brazilian Ministry of Health has previously stated that it will only consider the use of experimental vaccines from the University of Oxford and AstraZeneca Group PLC in the UK, and does not plan to purchase vaccines from Sinovac Biotech.
As early as the 19th, the Sao Paulo state government in Brazil has pointed out that 35% of the 9,000 volunteers who have undergone the Phase 3 human trial of Sinovac Biotech have side effects, including headaches and swelling at the injection site.
But the Butantan Institute announced on the same day that the "preliminary results of the late-stage clinical trials of this vaccine are safe", but the final conclusion will have to wait for the completion of various experiments. Subsequently, the governor of Sao Paulo declared that the federal government has approved the purchase of 46 million doses of Sinovac Biotech.
However, when the CCP was hyping the CCP’s successful export of vaccines, the Brazilian President suddenly announced that Brazil would never buy Chinese vaccines, which surprised the outside world.
Before this, the CCP used the CCP virus epidemic to engage in "mask diplomacy." However, because the quality of masks and protective clothing made in China is too low, the effect of "mask diplomacy" is not effective, which has caused many negative effects.
In addition to Sinovac Biotech, Chinese companies have several vaccines in phase 3 clinical trials, and their safety has not been recognized internationally. However, the CCP authorities cannot wait to promote vaccination among people who go abroad. Some local governments have also begun to liberalize "voluntary" vaccination for local people on a large scale.
Take Sinovac Biotech vaccine as an example. According to mainland Chinese media, since September, 743,000 people have been vaccinated with this vaccine in Yiwu, Jiaxing, Zhejiang and other places. The vaccine requires 2 doses, and the price is 400 RMB. However, official sources have not disclosed whether these vaccinated people have side effects.
According to a previous report by Hong Kong's Phoenix website, the 46 million doses of vaccines that Sinovac intends to provide to Brazil are US$2 per dose and US$4 for two doses, which is close to the "cabbage price."
No comments:
Post a Comment